Drug profile · INN
insulin glulisine
APIDRA
insulin glulisine (APIDRA) is a insulin receptor agonist. Associated with Sanofi-aventis Healthcare Pty Ltd.
EMA: approved TGA: approved Alimentary tract and metabolism (A10) A10AB06
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — insulin glulisine
- Class
- Alimentary tract and metabolism (A10)
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.83
Quick answer
insulin glulisine (APIDRA) is a insulin receptor agonist. Associated with Sanofi-aventis Healthcare Pty Ltd.
Key facts
INN insulin glulisine
Brand APIDRA
Mechanism Insulin receptor agonist
Target Insulin receptor
Therapeutic class Alimentary tract and metabolism (A10)
ATC code A10AB06
Originator Sanofi-aventis Healthcare Pty Ltd
Mechanism of action
Insulin receptor agonist
Primary target: Insulin receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is insulin glulisine?
insulin glulisine (APIDRA) is a insulin receptor agonist. Associated with Sanofi-aventis Healthcare Pty Ltd.
What is the brand name for insulin glulisine?
APIDRA is a marketed brand name for insulin glulisine. Check FDA Drugs@FDA for the current US label holder and prescribing information.